The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Open accessPublished version of a preprint
Abstract
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma, but the fraction of patients who derive clinical benefit remains undefined. Here, we report the experience of 860 patients with metastatic lung adenocarcinoma analyzed prospectively for mutations in >300 cancer-associated genes. Potentially actionable genetic events were stratified into one of four levels based upon published clinical or laboratory evidence that the mutation in question confers increased sensitivity to standard or investigational therapies. Overall, 37.1% (319/860) of patients received a matched therapy guided by their tumor molecular profile. Excluding alterations associated with standard-of-care therapy, 14.4% (69/478) received matched therapy, with a clinical benefit of 52%. Use of matched therapy was strongly influenced by the level of preexistent clinical evidence that the mutation identified predicts for drug response. Analysis of genes mutated significantly more often in tumors without known actionable mutations nominated STK11 and KEAP1 as possible targetable mitogenic drivers. Significance: An increasing number of therapies that target molecular alterations required for tumor maintenance and progression have demonstrated clinical activity in patients with lung adenocarcinoma. The data reported here suggest that broader, early testing for molecular alterations that have not yet been recognized as standard-of-care predictive biomarkers of drug response could accelerate the development of targeted agents for rare mutational events and could result in improved clinical outcomes. Cancer Discov; 7(6); 596–609. ©2017 AACR. See related commentary by Liu et al., p. 555. This article is highlighted in the In This Issue feature, p. 539
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [62]
Experimental — accuracy not yet measuredIn the citing paper
“KRAS mutations predominate in NSCLCs, accounting for ~78% of all RAS mutations found in such tumours17. The activating missense KRAS mutations that occur in ~25% of NSCLCs19–23 are typically mutually exclusive with other clinically actionable driver mutations, such as those in EGFR, BRAF and ALK24.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [21]
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Somatic mutations in LKB1 and KEAP1 significantly co-occur with mutant KRAS and with each other in NSCLC15, 59, 63, 91.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Activating mutations in KRAS are the most prevalent oncogenic driver event in both early-stage and metastatic LUAD, occurring in 25–32% of tumors34, 59, 60, 62, 67.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
In the citing paper
“Although EGFR –mutant tumors represent the prototypical oncogene-addicted LUAD subgroup that spearheaded adoption of the single-driver model, the overwhelming majority of EGFR-mutant lung tumors harbor one or more co-mutations, even when the analysis is limited to pre-defined sets of cancer-relevant genes within established panels (FoundationOne, Guardant360, MSK-IMPACT)15, 59, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Self-citationIntegrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationComprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
Cheng, D. T., Mitchell, T. N., Zehir, A., Shah, R. H., Benayed, R., Syed, A., Chandramohan, R., Liu, Z. Y., Won, H. H., Scott, S. N., et al. (2015) · The Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.12.006 · Cited by 2,119
Self-citationUsing Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., et al. (2014) · JAMA · doi:10.1001/jama.2014.3741 · Cited by 1,724
Self-citation
Research works printed but not linked: 2
- OncoKB.org, 2016, Precision Oncology Knowledge Base [Internet]
- Banno, 2016, : 10.1111/.12980, Sensitivities to various EGFR-TKIs of uncommon EGFR mutations L861Q and S768I: what is the optimal EGFR-TKI?, Cancer Sci · DOI
Cited by
Sorted by citations
Items 501–600 of 645
Instituto Nacional de Enfermedades Neoplásicas, D. D. P. L., Barrionuevo, C., Hancco, D. D., & Instituto Nacional de Enfermedades Neoplásicas, D. D. P. L. (2019) · Horizonte Médico (Lima) · doi:10.24265/horizmed.2019.v19n4.11 · Cited by 2
Song, I. H., Hong, S. H., Lee, K. Y., Kang, J. K., Lee, S. H., Lee, J., & Lee, A. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.152835 · Cited by 2
MUSTARD—a comprehensive resource of mutation-specific therapies in cancer
Mittal, G., I, A. R., Vatsyayan, A., Pandhare, K., & Scaria, V. (2021) · Database · doi:10.1093/database/baab042 · Cited by 2
Hamada, A., Suda, K., Koga, T., Fujino, T., Nishino, M., Ohara, S., Chiba, M., Shimoji, M., Takemoto, T., Soh, J., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.10.014 · Cited by 3
The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer
Tam, A., Eustace, N. J., Kassardjian, A., West, H., Williams, T. M., & Amini, A. (2023) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2023.02.004 · Cited by 2
Agostara, A. G., Roazzi, L., Villa, F., Romanò, R., Piscazzi, D., Martinelli, F., Ciarlo, G., Oresti, S., Travaglini, F., Marando, A., et al. (2023) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2023.2268509 · Cited by 2
E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma
Lin, S., Yu, X., Yan, H., Xu, Y., Ma, K., Wang, X., Liu, Y., Xie, A., & Yu, Z. (2024) · Medicine · doi:10.1097/md.0000000000034342 · Cited by 2
Kondo, T., Kikuchi, O., Yamamoto, Y., Sunami, T., Wang, Y., Fukuyama, K., Saito, T., Nakahara, H., Minamiguchi, S., Kanai, M., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae113 · Cited by 2
Munkhjargal, B., Kondo, K., Soejima, S., Tegshee, B., Yamashita, M., Kawakita, N., Toba, H., & Takizawa, H. (2024) · Oncology Reports · doi:10.3892/or.2024.8790 · Cited by 2
Fujiwara, Y., Masago, K., Matsuzawa, R., Yamaguchi, T., Watanabe, N., Shimizu, J., Sasaki, E., & Horio, Y. (2024) · Case Reports in Oncology · doi:10.1159/000540445 · Cited by 2
Chen, G., Yu, Y., Qi, Y., Li, G., Li, N., Meng, F., Wang, W., & Shen, R. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1393686 · Cited by 2
Ou, H., Tsai, J.-H., Chen, Y.-L., Wu, T.-I., Chen, L.-J., & Yang, S. (2025) · PharmacoEconomics · doi:10.1007/s40273-024-01462-z · Cited by 2
Melosky, B. L., Juergens, R. A., Banerji, S. O., Sacher, A. G., Wheatley‐Price, P., Snow, S. L., Tsao, M., Leighl, N. B., Martins, I., Cheema, P. K., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308784 · Cited by 2
Lu, Y., Fang, D., Guo, J., & Huang, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1441182 · Cited by 2
Hu, C., Lu, C., Zheng, J., Kang, J., Huang, D., He, C., Liu, Y., Liu, Z.-R., Wu, D., Dou, Y., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01511-z · Cited by 2
[Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma].
Yu, L., Hou, H., Jiang, M., Zhang, C., Liu, D., & Zhang, X. (2020) · PubMed Central · doi:10.3779/j.issn.1009-3419.2020.101.17 · Cited by 2
Wu, H., Ye, Q., Razzano, D., Tugal, O., Rosenblum, J., Weigel, T. L., & Zhong, M. (2020) · Pediatric and Developmental Pathology · doi:10.1177/1093526620957219 · Cited by 2
The Keap1-Nrf2 Signaling Pathway in Lung Cancer
Raghunath, A., Raju, N., & Sundarraj, K. (2021) · Springer eBooks · doi:10.1007/978-981-33-6827-9_30 · Cited by 2
Elkrief, A., Makhnin, A., Moses, K. A., Ahn, L. S. H., Preeshagul, I. R., Iqbal, A. N., Hayes, S. A., Plodkowski, A. J., Paik, P. K., Ladanyi, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3484 · Cited by 2
Self-citationSperduto, P. W., & Lou, E. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab054 · Cited by 2
Deng, R., Zhang, W., Lv, J., Wang, F., Chen, Y., Jiang, C., Guan, Y., & Zhang, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e35304 · Cited by 1
Define, C. (2025) · International Journal of Clinical Medical Research · doi:10.61466/ijcmr3010005 · Cited by 1
An evaluation of patritumab deruxtecan for the treatment of EGFR -mutated non-small cell lung cancer
Waissengrin, B., & Reckamp, K. L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2507833 · Cited by 1
Emerging Targets in Non-Small Cell Lung Cancer
Wang, J., Biglow, L. R., & Baumgart, M. A. (2025) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s511767 · Cited by 1
Zhang, S., Li, R., Cui, H., & Li, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1673115 · Cited by 1
Hu, L., Pei, Y., Wang, X., Liu, Q., Cao, W., Liu, Y., Kou, F., Liao, X., Zhang, Y., Rui, J., et al. (2025) · The Innovation Medicine · doi:10.59717/j.xinn-med.2025.100163 · Cited by 1
Small Cell Lung Cancer Classification: Unraveling Heterogeneity to Enable Personalized Treatments
Boettiger, K., Kovács, I., Horváth, L., Ernhofer, B., Schelch, K., Pozonec, M. D., Teglas, V., Aigner, C., Megyesfalvi, E., Rényi-Vámos, F., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-1483 · Cited by 1
Seker, K., Babacan, Ö. U., & Hasbek, Z. (2026) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2025.500276 · Cited by 1
Bridging the gap between tumor evolution and clonality diagnostics in multiple lung carcinomas
Janssen, J., Allgäuer, M., Ylstra, B., Draijer, S., Kim, Y., Budczies, J., Kazdal, D. N., Stenzinger, A., Kirchner, M., & Radonic, T. R. (2026) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2026.03.003 · Cited by 1
Gentile, G., Gelibter, A., Marchis, L. D., Pappalardo, L., Capasso, C., Giusti, R., Botticelli, A., Mazzuca, F., Santini, D., & Siringo, M. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105307 · Cited by 1
Lau, L. Y., Sahib, N. R. B. M., Cangco, C. Y. P., & Tan, A. C. (2026) · Drugs · doi:10.1007/s40265-026-02329-7 · Cited by 1
Gürçay, N., Demirağ, F., Yilmaz, M., Öz, İ., Cengiz, T. İ., Koçanoğlu, A., Karakaya, S., & Demir, Ö. F. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135236 · Cited by 1
Klempner, S. J., Gowen, K. A., Lee, T. K. M., Zhu, V. W., Schrock, A. B., Miller, V. A., Ali, S. M., & Ou, S. I. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.043 · Cited by 1
Secuenciación de nueva generación (NGS) y oncología de precisión
Recondo, G. (2021) · Medicina · doi:10.56050/01205498.1572 · Cited by 1
Management of Non-Small Cell Lung Cancer: Updates from the European Lung Cancer Congress 2022
Arora, S., Asawa, P., Kataria, N., Hendriks, L. E. L., & Desai, A. P. (2022) · Cancer Investigation · doi:10.1080/07357907.2022.2077566 · Cited by 1
Nabatchian, F., Davoudi, M., Ashtiani, M., Davoudi, N., & Afrisham, R. (2023) · Current Chemical Biology · doi:10.2174/2212796817666230214100146 · Cited by 1
Damiola, F., Alberti, L., Mansuet‐Lupo, A., Damotte, D., Hofman, V., Tixier, L., Penault-Llorca, F. M., Rouquette, I., Vignaud, J.-M., Cazes, A., et al. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2277367 · Cited by 1
Molecular Pathology of Lung Tumors
Lo, Y., & Lindeman, N. I. (2023) · Springer eBooks · doi:10.1007/978-3-031-35118-1_9 · Cited by 1
Колбин, А. С., Gomon, Y. М., Proskurin, M. A., & Balykina, Y. Е. (2023) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2023.210 · Cited by 1
Tang, S., Tang, C., Lin, Z., & Jiang, J. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2023.101.35 · Cited by 1
Ko, E.-J., Kwag, E.-B., Park, J., Cho, S.-H., Park, S.-J., Jeong, M.-K., Kang, I., & Yoo, H. (2025) · Integrative Cancer Therapies · doi:10.1177/15347354241307006 · Cited by 1
Kaneda, H., Daga, H., Okada, A., Nakatani, Y., Tani, Y., Oka, T., Sawa, K., Sakai, K., Nishio, K., & Kawaguchi, T. (2025) · Investigational New Drugs · doi:10.1007/s10637-025-01505-y · Cited by 1
Spira, A. I., Waters, D. D., Tao, R., Vadagam, P., He, J., Vanderpoel, J., Donnelly, A., & Lin, I. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100944 · Cited by 1
Isaacs, J. M., & Clarke, J. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-800684-9.00006-x · Cited by 1
Circulating Cell-Free Tumor DNA in the Management of Double Primary Tumors
Dudnik, E., Twito, T., Faull, I., Dvir, A., Soussan‐Gutman, L., Purim, O., & Lanman, R. B. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00238 · Cited by 1
Complete Pathological Response to Crizotinib in a Patient with ALK-rearranged Lung Adenocarcinoma
Mattar, M. S., Chang, J. C., Benayed, R., Halpenny, D. F., Powers, A. S., Kleiner, D. E., Drilon, A. E. D. C., & Kris, M. G. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.10.002 · Cited by 1
Self-citationKato, Y., Kato, T., Tanaka, H., Kajikawa, S., Yonezawa, T., Yamamoto, Y., Tsuzuki, T., Yamaguchi, E., Kubo, A., & Ito, S. (2020) · Haigan · doi:10.2482/haigan.60.411 · Cited by 1
Haploinsufficiency Interactions of RALBP1 and TP53 in Carcinogenesis
Awasthi, S. (2021) · Cancers · doi:10.3390/cancers13020255 · Cited by 1
ROS1 at the Crossroads of Clinical Oncology, Molecular Diagnostics, and Drug Development
Odintsov, I., Somwar, R., Ladanyi, M., & Drilon, A. E. D. C. (2021) · JCO Oncology Practice · doi:10.1200/op.20.00969 · Cited by 1
Self-citationFang, S.-F., Peng, W., Xiong, Y.-Z., Nie, X., & Huang, J. (2021) · Zeitschrift für Kristallographie - New Crystal Structures · doi:10.1515/ncrs-2021-0085 · Cited by 1
Xu, X., Zhao, Y., Ye, H., Qi, Y., Xu, W., Ling, Y., & Yang, S. (2022) · Computational and Mathematical Methods in Medicine · doi:10.1155/2022/7451395 · Cited by 1
RetractedJovanović, D. M. (2023) · AME Surgical Journal · doi:10.21037/asj-21-114
Precision medicine in immunotherapy and lung cancer
Sánchez‐Céspedes, M. (2023) · Anales de la Real Academia Nacional de Farmacia · doi:10.53519/analesranf.2023.89.01.01
[Effect of calmodulin on myometrial cell membrane Ca2+,Mg2+-ATPase activity].
Kravtsov, O. V., & Kravtsova, V. V. (2000) · PubMed · Cited by 1
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS -mutant lung cancersPreprint
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., Clark, S. E., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.29.510137 · Cited by 1
Loss of the endocytic tumor suppressor HD-PTP phenocopies LKB1 and promotes RAS-driven oncogenesisPreprint
Seong, C.-S., Huang, C., Boese, A. C., Hou, Y., Koo, J., Mouw, J. K., Rupji, M., Joseph, G., Johnston, H. R., Claussen, H., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.26.525772 · Cited by 1
Somatic Mutation But Not Aneuploidy Differentiates Lung Cancer in Never-Smokers and SmokersPreprint
Moorthi, S., Paguirigan, A. L., Ko, M., Pettinger, M. B., Hoge, A. C. H., Nag, A., Patel, N. A., Wu, F., Sather, C. L., Fitzgibbon, M., et al. (2023) · SSRN Electronic Journal · doi:10.1101/2023.01.05.522947 · Cited by 1
Sadeghi, S., Kiaei, A. A., Boush, M., Salari, N., Mohammadi, M., Safaei, D., Mahboubi, M., Tajfam, A., & Moghadam, S. (2024) · medRxiv · doi:10.1101/2024.04.14.24304384 · Cited by 1
Dasari, K., Alfaro-Murillo, J. A., & Townsend, J. P. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.27.625765 · Cited by 1
Zhang, Z., Wang, X., Li, C., Ripley, R. T., Wu, J., Zhang, J., Amos, C. I., & Cheng, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.21.671519 · Cited by 1
MET ex14-Positive NSCLC: Time to Take the Therapy to the Target to Aim for a Cure?
Zhu, V. W., & Ou, S. I. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.06.009
Molecular Diagnostics in Lung Cytology
VanderLaan, P. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-97397-5_11
Akamatsu, H., AMANO, J., Suzuki, A., & Kikushima, Y. (1994) · PubMed
Hayashi, T., & Kato, S. (2020) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.2020.66.jmj20-r01
Zhang, D., Wang, X., Ma, S., Li, P., Xue, F., Mao, B., Guan, X., Zhou, W., Peng, J., Su, K., et al. (2021) · PubMed Central · doi:10.3892/ol.2021.12440
Zheng, Y., Huang, Y., Bian, Y., Du, Y., Lu, T., Sui, Q., Li, M., Chen, Z., Zhan, C., Xi, J., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-3957
Oncogenic variants guiding treatment in thoracic malignancies
Meng, P. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.160074057
Molecular mechanisms of lung cancer
Лосев, О. Э., Бородулин, В. Б., Юрьевна, Р. Н., Бобылева, Е. В., & Владимирович, Б. Я. (2021) · Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» · doi:10.25557/0031-2991.2021.01.124-132
郭, 李. (2021) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2021.93014
Klinische Studien auf der Basis molekularer Charakterisierung von Tumoren
Dittrich, C. (2021) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_389-1
Arcila, M. E., Chang, J. C., & Tafe, L. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-22922-1_6
Self-citationDobra, K., & Hjerpe, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-76478-8_8
Occhipinti, M. A., Ferrara, R., Imbimbo, M., Simeon, V., Fiscon, G., Marchal, C., Skoetz, N., & Viscardi, G. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015140
Clinical decision-making strategies for rare somatic variants in cancer
Koopman, H. F. J. M. (2022) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.213504207
Doi, Y., Tagaya, H., Noge, A., & Semba, K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.05.26.493531
[Current Progress and Future Developments of Antibody Drug Conjugates in Lung Cancer].
Zhu, Y., & Wang, Z. (2022) · PubMed Central · doi:10.3779/j.issn.1009-3419.2022.102.22
Molecular Diagnostics in Cancer
Coyne, Z. L., Kalachand, R. D., Bast, R. C., Mills, G. B., & Hennessy, B. T. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm041.pub2
Hernandez, L. G., & Young, M. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2022.22251
Manjunatha, B. K., Kanagasabapathy, V., Gomathi, A., Ramachandrappa, D., Gurumurthy, P., Kumar, R. K. K., Narayan, U., Shanmugam, K., & Pillai, G. G. (2022) · Asia-Pacific Journal of Molecular Biology and Biotechnology · doi:10.35118/apjmbb.2022.030.4.07
Spotti, M., Minatta, J. N., Rizzo, M., Castagneris, N., Sena, S. N., Recondo, G., & Bluthgen, M. V. (2022) · Oncología Clínica · doi:10.56969/oc.v27i2.79
Liu, X., Li, Z., Wang, Z., Liu, F., Zhang, L., Ke, J., Xu, X., Zhang, Y., Yuan, Y., Wei, T., et al. (2023) · doi:10.1158/0008-5472.c.6513780.v1
Self-citationSitthideatphaiboon, P., Galán‐Cobo, A., Negrao, M. V., Qu, X., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., et al. (2023) · doi:10.1158/1078-0432.c.6530724
Chang, J. C., Offin, M. D., Falcon, C. J., Brown, D. N., Houck-Loomis, B. R., Meng, F., Rudneva, V. A., Won, H. H., Amir, S., Montecalvo, J., et al. (2023) · doi:10.1158/1078-0432.c.6530487.v1
Self-citationSitthideatphaiboon, P., Galán‐Cobo, A., Negrao, M. V., Qu, X., Poteete, A., Zhang, F., Liu, D. D., Lewis, W. E., Kemp, H. N., Lewis, J., et al. (2023) · doi:10.1158/1078-0432.c.6530724.v1
Su, Y., Wang, W., Shen, Q., Lei, Z., Li, J., Zhang, W., Zhang, F.-X., Xu, B., & Hu, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2803361/v1
Clinical significance of TMEM229A Q200del mutation in lung adenocarcinomaPreprint
Liang, Y., Xie, Y., Yu, H., Zhu, W., Yin, C., Zhang, X., & Dong, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-3071539/v1
Self-citationFebbraro, M., Juergens, R. A., & Pond, G. R. (2023) · Medical Research Archives · doi:10.18103/mra.v11i7.2.4130
Molecular Carcinogenesis of Lung Cancer
Akyürek, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-22483-6_59-1
Histology and molecular testing
Cabanero, M., Pal, P., & Tsao, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-69573-2.00012-7
Kang, X.-H., Zhang, M., Li, R., Bai, H., Li, T., Zhang, F.-S., Niu, Z.-G., & Qu, Y.-Q. (2023) · Research Square · doi:10.21203/rs.3.rs-3474092/v1
Xie, F., Su, Y., Xie, L., Shen, Q., Lei, Z., Li, J., Zhang, W., Xu, B., & Hu, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2803361/v2
Tang, Y.-J., Chang, J. W., Huang, C., Fang, Y., Chang, C., Yang, C., Kuo, C. S., Hsu, P., & Wu, C. (2024) · Journal of Cancer Research and Practice · doi:10.4103/ejcrp.ejcrp-d-23-00043
Shen, F., Guo, W., Song, X., & Wang, B. (2023) · Figshare · doi:10.6084/m9.figshare.23498186
Hareem, S., Akula, V., Annamaneni, S., Puligundla, K. C., & Kancha, R. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-1802-3_1
Genetic diversity in small cell lung carcinoma
Hayashi, T. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-24-40
[Research Progress of Antibody-conjugated Drugs in Non-small Cell Lung Cancer].
Liu, Y., & Wei, S. (2024) · PubMed Central · doi:10.3779/j.issn.1009-3419.2024.102.22
Li, C., Chen, J. S., Zhang, G., Guo, F., & Zhang, X. (2024) · medRxiv · doi:10.1101/2024.08.18.24312183
Hussain, M., Mackrides, N., Su, S., & Seth, A. (2024) · Cureus · doi:10.7759/cureus.70896
Nazaruddin, I., Karuniawati, S. D., & Yani, I. (2024) · SHS Web of Conferences · doi:10.1051/shsconf/202420101009
MGMT Promoter Methylation Predicts Survival in Lung Adenocarcinoma
Hekim, S., & Mamatjan, Y. (2025) · doi:10.1109/cihmcompanion65205.2025.11002696
Metadata
- Authors
- Jordan, E. J., Kim, H. R., Arcila, M. E., Barron, D., Chakravarty, D., Gao, J., Chang, M. T., Ni, A., Kundra, R., Jonsson, P., Jayakumaran, G., Gao, S. P., Johnsen, H. C., Hanrahan, A. J., Zehir, A., Rekhtman, N., Ginsberg, M. S., Li, B. T., Yu, H. A., Paik, P. K., Drilon, A., Hellmann, M. D., Reales, D. N., Benayed, R., Rusch, V. W., Kris, M. G., Chaft, J. E., Baselga, J., Taylor, B. S., Schultz, N., Rudin, C. M., Hyman, D. M., Berger, M. F., Solit, D. B., Ladanyi, M., & Riely, G. J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- 6Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
- 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Corresponding author
- Riely, Gregory J.
- ORCID
- Jordan, Emmet J.
- Kim, Hyunjae R.
- Arcila, Maria E.
- Chakravarty, Debyani
- Gao, JianJiong
- Kundra, Ritika
- Jonsson, Philip
- Jayakumaran, Gowtham
- Zehir, Ahmet
- Rekhtman, Natasha
- Ginsberg, Michelle S.
- Li, Bob T.
- Yu, Helena A.
- Paik, Paul K.
- Drilon, Alexander
- Hellmann, Matthew D.
- Reales, Dalicia N.
- Benayed, Ryma
- Rusch, Valerie W.
- Kris, Mark G.
- Chaft, Jamie E.
- Taylor, Barry S.
- Schultz, Nikolaus
- Rudin, Charles M.
- Hyman, David M.
- Berger, Michael F.
- Solit, David B.
- Ladanyi, Marc
- Riely, Gregory J.
- Venue
- Cancer Discovery
- Published
- 2017-06-01
- Volume
- 7
- Issue
- 6
- Pages
- 596-609
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5482929
- OpenAlex
- W2603411876
- Cited by
- 643
- References
- 49
- Citations by year
- 2026: 30 · 2025: 40 · 2024: 65 · 2023: 99 · 2022: 94 · 2021: 101 · 2020: 79 · 2019: 65 · 2018: 55 · 2017: 12
- FWCI
- 47.73
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR002384)
- National Cancer Institute (P30CA008748)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- lung adenocarcinoma, metastatic lung cancer, actionable mutations, targeted therapy, predictive biomarkers, drug response, STK11, Keap1, clinical benefit, molecular profiling
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Adolescent, Adult, Aged, Female, Genetic Testing, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Biomarkers, Tumor, Young Adult, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
